CliffBio
small molecule

EUCRISA

CRISABOROLE

Loss of exclusivityJuly 2030latest FDA-listed patent expiry
CompanyAnacor Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameEUCRISA
Active ingredientCRISABOROLE
Strength2%
Dosage formOINTMENT
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2016
Marketing statusRX

Listed patents

PatentExpiresType
8168614*PEDJuly 2030—
8168614January 2030use U-1932
8039451*PEDDecember 2029—
8039451June 2029substance, product
9682092*PEDAugust 2027—
8501712*PEDAugust 2027—
8501712February 2027use U-1932
9682092February 2027use U-1932

Regulatory exclusivity

CodeExpires
D-191April 2026

More from Anacor Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EUCRISA patent cliff — loss of exclusivity July 2030 | CliffBio